Goldman Sachs Maintained a Buy Rating on Eli Lilly (LLY), Kept the PT Unchanged

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for High Returns. On July 31, Asad Haider of Goldman Sachs maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $833.

The analyst highlighted that the company’s recent SURPASS-CVOT trial showed Mounjaro is not inferior to Trulicity and reduced major cardiovascular events by 8%. He noted that although the results were not statistically significant it removed a major uncertainty regarding the company.

Moreover, the analyst also expects strong performance from Eli Lilly and Company’s (NYSE:LLY) 2Q25 earnings report and is also watching for management’s guidance for the year. He also views the results for the ATTAIN-1 trial as significant as it tests the company’s drug for oral obesity pill.

Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical firm that discovers, develops, manufactures, and markets medicines.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.